Search

Your search keyword '"Choudry M"' showing total 163 results
Start Over Author "Choudry M"
163 results on '"Choudry M"'

1. Insight into Predictors of Cytoreduction Score Following Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy for Gastric Peritoneal Carcinomatosis Improves Patient Selection and Prognostic Outcomes

Author

Hamed, Ahmed B., El Asmar, Rudy, Tirukkovalur, Nikhil, Tcharni, Adam, Tatsuoka, Curtis, Jelinek, Mark, Derby, Joshua, Dubrovsky, Genia, Nunns, Geoffrey, Ongchin, Melanie, Pingpank, James F., Zureikat, Amer H., Bartlett, David L., Singhi, Aatur, Choudry, M. Haroon, and AlMasri, Samer S.

Published
2024
Full Text
View/download PDF

2. ASO Visual Abstract: Insight into Predictors of Cytoreduction Score Following Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy for Gastric Peritoneal Carcinomatosis Improves Patient Selection and Prognostic Outcomes

Author

Hamed, Ahmed B., Asmar, Rudy El, Tirukkovalur, Nikhil, Tcharni, Adam, Tatsuoka, Curtis, Jelinek, Mark, Derby, Joshua, Dubrovsky, Genia, Nunns, Geoffrey, Ongchin, Melanie, Pingpank, James F., Zureikat, Amer H., Bartlett, David L., Singhi, Aatur, Choudry, M. Haroon, and AlMasri, Samer S.

Published
2024
Full Text
View/download PDF

4. Targeted Next-Generation Sequencing Improves the Prognostication of Patients with Disseminated Appendiceal Mucinous Neoplasms (Pseudomyxoma Peritonei)

Author

Wald, Abigail I., Pingpank, James F., Ongchin, Melanie, Hall, Lauren B., Jones, Heather, Altpeter, Shannon, Liebdzinski, Michelle, Hamed, Ahmed B., Derby, Joshua, Nikiforova, Marina N., Bell, Phoenix D., Paniccia, Alessandro, Zureikat, Amer H., Gorantla, Vikram C., Rhee, John C., Thomas, Roby, Bartlett, David L., Smith, Katelyn, Henn, Patrick, Theisen, Brian K., Shyu, Susan, Shalaby, Akram, Choudry, M. Haroon A., and Singhi, Aatur D.

Published
2023
Full Text
View/download PDF

7. ASO Visual Abstract: Targeted Next-Generation Sequencing Improves the Prognostication of Patients with Disseminated Appendiceal Mucinous Neoplasms (Pseudomyxoma Peritonei)

Author

Wald, Abigail I., Pingpank, James F., Ongchin, Melanie, Hall, Lauren B., Jones, Heather, Altpeter, Shannon, Liebdzinski, Michelle, Hamed, Ahmed B., Derby, Joshua, Nikiforova, Marina N., Bell, Phoenix D., Paniccia, Alessandro, Zureikat, Amer H., Gorantla, Vikram C., Rhee, John C., Thomas, Roby, Bartlett, David L., Smith, Katelyn, Henn, Patrick, Theisen, Brian K., Shyu, Susan, Shalaby, Akram, Choudry, M. Haroon A., and Singhi, Aatur D.

Published
2023
Full Text
View/download PDF

24. Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case–Control Study

Author

Dhir, Mashaal, Jones, Heather L., Shuai, Yongli, Clifford, Amber K., Perkins, Samantha, Steve, Jennifer, Hogg, Melissa E., Choudry, M. Haroon A., Pingpank, James F., Holtzman, Matthew P., Zeh, III, Herbert J., Bahary, Nathan, Bartlett, David L., and Zureikat, Amer H.

Published
2017
Full Text
View/download PDF

25. Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

Author

Davar, Diwakar, primary, Karunamurthy, Arivarasan, additional, Chauvin, Joe-Marc, additional, Morrison, Robert, additional, Bai, Yulong, additional, Sun, Jie, additional, Stein, Julie, additional, Rodrigues, Richard, additional, McCulloch, John, additional, Wang, Hong, additional, Hartman, Douglas, additional, Fernandes, Miriam, additional, Cole, Alicia, additional, Dzutsev, Amiran, additional, Deitrick, Christopher, additional, Bao, Riyue, additional, Duvvuri, Umamaheswar, additional, Sridha, Shaum, additional, Kim, Seungwon, additional, Choudry, M. Haroon, additional, Holtzman, Matthew, additional, Pingpank, James, additional, O'Toole, James, additional, DeBlasio, Richelle, additional, Jin, Yang, additional, Ding, Quanquan, additional, Gao, Wentao, additional, Groetsch, Christopher, additional, Pagliano, Ornella, additional, Rose, Amy, additional, Urban, Corey, additional, Singh, Jagjit, additional, Divakar, Prajan, additional, Mauro, David, additional, Bobilev, Dmitri, additional, Wooldridge, James, additional, Krieg, Arthur, additional, Fury, Matthew, additional, Najjar, Yana, additional, Luke, Jason, additional, Kirkwood, John, additional, Taube, Janis, additional, Park, Hyun Jung, additional, Trinchieri, Giorgio, additional, and Zarour, Hassane, additional

Published
2022
Full Text
View/download PDF

28. High Grade Dysplastic Nodule in a Non-Cirrhotic Liver in the Young

Author

Choudry M and Navarro J

Subjects
General Medicine
Abstract

Patients with high grade dysplastic nodule (HGDN) have an increased risk for development of hepatocellular carcinoma. Hepatocellular carcinoma (HCC) in a young patient with no cirrhosis or fibrosis is a relatively rare condition. HCC develops in patients in the setting of liver cirrhosis with established risk factors related to various etiologies including hepatitis virus infection, high alcohol intake or metabolic diseases. This was a case of a 29-year-old male with a 7-month history of intermittent right upper quadrant pain with CT scan findings of caudate lobe mass with malignant features. The patient underwent extended left hepatectomy with caudate lobectomy. Patient was discharged on fifth postoperative day, and was advised for follow-up surveillance on an outpatient basis. Liver cirrhosis is the main risk factor for developing HGDN, although rare cases of HGDN in a non-cirrhotic young patient should not be disregarded. Even though, it difficult to differentiate HGDN from early HCC based on radiologic imaging and histopathological criteria. Early diagnosis accompanied with proper surgical intervention such as anatomic resection and regular surveillance should be considered in the course and management of these patients, despite its rarity

Published
2022
Full Text
View/download PDF

31. Definition and Prediction of Early Recurrence and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: Towards Predicting Oncologic Futility Preoperatively

Author

Rieser, Caroline J., primary, Jones, Heather, additional, Hall, Lauren B., additional, Kang, Eliza, additional, Altpeter, Shannon, additional, Zureikat, Amer H., additional, Holtzman, Matthew P., additional, Lee, Andrew, additional, Ongchin, Melanie, additional, Pingpank, James F., additional, Choudry, M. Haroon A., additional, and Bartlett, David L., additional

Published
2021
Full Text
View/download PDF

39. Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risk Primary Appendiceal Neoplasms After Complete Resection

Author

Enomoto, Laura M., primary, Choudry, M. Haroon, additional, Bartlett, David L., additional, Totin, Linsay, additional, Mann, Gary N., additional, Skitzki, Joseph J., additional, Perry, Kathleen C., additional, Votanopoulos, Konstantinos I., additional, Levine, Edward A., additional, and Shen, Perry, additional

Published
2019
Full Text
View/download PDF

40. PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries

Author

Brendan Moran, Lekshmi Ramalingam, David L. Bartlett, Perry Shen, Choudry M. Haroon, James F. Pingpank, Edward A. Levine, Konstantinos I. Votanopoulos, Konstantinos Chouliaras, Chandrakumaran Kandiah, and Greg Russell

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, 030230 surgery, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Surgical oncology, otorhinolaryngologic diseases, medicine, Combined Modality Therapy, Humans, In patient, Survival rate, Peritoneal Neoplasms, Retrospective Studies, Chemotherapy, business.industry, Retrospective cohort study, Cytoreduction Surgical Procedures, Hyperthermia, Induced, Middle Aged, Prognosis, Survival Rate, Oncology, Appendiceal Neoplasms, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Chemotherapy, Cancer, Regional Perfusion, Conventional PCI, Surgery, Hyperthermic intraperitoneal chemotherapy, Female, Radiology, business, Follow-Up Studies
Abstract

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is a treatment option in patients with carcinomatosis from high-grade appendiceal (HGA) primaries. It is unknown if there is a Peritoneal Carcinomatosis Index (PCI) upper limit above which a complete CRS/HIPEC does not assure long-term survival.Retrospective analysis from three centers was performed. The PCI was used to grade volume of of disease. Survival in relation to PCI was studied on patients with complete cytoreduction.Overall, 521 HGA patients underwent CRS/HIPEC from 1993 to 2015, with complete CRS being achieved in 50% (260/622). Mean PCI was 14.8 (standard deviation 8.7, range 0-36). Median survival for the complete CRS cohort was 6.1 years, while 5- and 10-year survival was 51.7% (standard error [SE] 4.6) and 36.1% (SE 6.3), respectively. Arbitrary cut-off PCI limits with 5-point splits (p = 0.63) were not predictive of a detrimental effect on survival as long as a complete CRS was achieved. A linear effect of the PCI on survival (p = 0.62) was not observed, and single-point PCI cohort splits within a PCI range of 5 to 10 were not predictive of survival for complete CRS patients. The PCI correlated with the ability to achieve a complete CRS, with a mean PCI of 14.7 (8.7) for completeness of cytoreduction (CC)0, 22.3 (7.8) for CC1 and 26.1 (9.5) for CC2/3 resections (p = 0.0001, hazard ratio 1.12, 95% confidence interval 1.09), with an HR of 1.15 for each 1-unit increase in the PCI score. Only 21% of the cohort achieved a complete CRS with a PCI ≥ 21.The PCI correlates with the ability to achieve a complete CRS in carcinomatosis from HGA. PCI is not associated with survival as long as a complete CRS can be achieved.

Published
2017

41. The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases.

Author

Izquierdo, Francisco J., Schuitevoerder, Darryl, Plana, Alejandro, Sherman, Scott K., White, Michael G., Baumgartner, Joel M., Choudry, M. Haroon A., Abbott, Daniel E., Barone, Robert M., Berri, Richard N., Chan, Carlos H. F., Clarke, Callisia N., Cloyd, Jordan M., Fleshman, James W., Georgakis, Georgios V., Idrees, Kamran, In, Haejin, Melnitchouk, Nelya, Salti, George, and Veerapong, Jula

Subjects
CANCER, COLON cancer, METASTASIS, PALLIATIVE treatment, ONCOLOGISTS, COLON tumors, COMPARATIVE studies, RESEARCH methodology, MEDICAL cooperation, MEDICAL protocols, RECTUM tumors, RESEARCH, PERITONEUM tumors, EVALUATION research
Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of colorectal cancer specifically as it relates to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

42. The Chicago Consensus Guidelines for Peritoneal Surface Malignancies: Introduction.

Author

Chicago Consensus Working Group, Turaga, Kiran, Ahuja, Nita, Richard Alexander, H., Abbott, Daniel E., Badgwell, Brian, Baumgartner, Joel M., Choudry, M. Haroon A., Cusack, James C., Deneve, Jeremiah L., Esquivel, Jesus, Foster, Jason M., Hanna, Nader, Hayes-Jordan, Andrea, Johnston, Fabian M., Labow, Daniel M, Lambert, Laura A., Lee, Byrne, Levine, Edward A., and Lowy, Andrew M.

Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of peritoneal surface malignancies of various causes. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. This article serves as an introduction to this effort. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

43. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases.

Author

Chicago Consensus Working Group, Izquierdo, Francisco J., Schuitevoerder, Darryl, Plana, Alejandro, Sherman, Scott K., White, Michael G., Baumgartner, Joel M., Choudry, M. Haroon A., Abbott, Daniel E., Barone, Robert M., Berri, Richard N., Chan, Carlos H. F., Clarke, Callisia N., Cloyd, Jordan M., Fleshman, James W., Georgakis, Georgios V., Idrees, Kamran, In, Haejin, Melnitchouk, Nelya, and Salti, George

Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of colorectal cancer specifically as it relates to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

44. PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries

Author

Votanopoulos, Konstantinos Ioannis, primary, Bartlett, David, additional, Moran, Brendan, additional, Haroon, Choudry M., additional, Russell, Greg, additional, Pingpank, James F., additional, Ramalingam, Lekshmi, additional, Kandiah, Chandrakumaran, additional, Chouliaras, Konstantinos, additional, Shen, Perry, additional, and Levine, Edward A., additional

Published
2017
Full Text
View/download PDF

46. Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case–Control Study

Author

Dhir, Mashaal, primary, Jones, Heather L., additional, Shuai, Yongli, additional, Clifford, Amber K., additional, Perkins, Samantha, additional, Steve, Jennifer, additional, Hogg, Melissa E., additional, Choudry, M. Haroon A., additional, Pingpank, James F., additional, Holtzman, Matthew P., additional, Zeh, Herbert J., additional, Bahary, Nathan, additional, Bartlett, David L., additional, and Zureikat, Amer H., additional

Published
2016
Full Text
View/download PDF

47. The Chicago Consensus Guidelines for peritoneal surface malignancies: Introduction.

Author

Turaga, Kiran, Ahuja, Nita, Richard Alexander, H., Abbott, Daniel E., Badgwell, Brian, Baumgartner, Joel M., Choudry, M. Haroon A., Cusack, James C., Deneve, Jeremiah L., Esquivel, Jesus, Foster, Jason M., Hanna, Nader, Hayes‐Jordan, Andrea, Johnston, Fabian M., Labow, Daniel M., Lambert, Laura A., Lee, Byrne, Levine, Edward A., Lowy, Andrew M., and Nash, Garrett M.

Subjects
CANCER, GUIDELINES, PALLIATIVE treatment, PATHOLOGISTS, ONCOLOGISTS, COMPARATIVE studies, RESEARCH methodology, MEDICAL cooperation, MEDICAL protocols, RESEARCH, PERITONEUM tumors, EVALUATION research
Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of peritoneal surface malignancies of various causes. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. This article serves as an introduction to this effort. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

48. Effectiveness of Hepatic Artery Infusion (HAI) Versus Selective Internal Radiation Therapy (Y90) for Pretreated Isolated Unresectable Colorectal Liver Metastases (IU-CRCLM).

Author

Dhir, Mashaal, Zenati, Mazen S., Jones, Heather L., Bartlett, David L., Choudry, M. Haroon A., Pingpank, James F., Holtzman, Matthew P., Bahary, Nathan, Hogg, Melissa E., Zeh, Herbert J., Geller, David A., Wallis Marsh, J., Tsung, Allan, and Zureikat, Amer H.

Abstract

Background: In the era of modern effective systemic chemotherapy, the comparative effectiveness of hepatic artery infusion (HAI) versus selective internal radiation therapy (yttrium-90 [Y90]) for pretreated patients with isolated unresectable colorectal liver metastasis (IU-CRCLM) remains unknown. This study sought to compare the overall survival (OS) after HAI versus Y90 for IU-CRCLM patients treated with modern chemotherapy and to perform a cost analysis of both regional methods. Methods: This study retrospectively reviewed patients receiving HAI or Y90 in combination with modern chemotherapy as second-line therapy for IU-CRCLM. Overall survival was calculated from the time of IU-CRCLM diagnosis. Uni- and multivariate models were constructed to identify independent predictors of survival. Results: The inclusion criteria were met by 97 patients (48 HAI patients and 49 Y90 patients). Both groups were similar in terms of age, gender, body mass index (BMI), synchronous disease, carcinoembryonic antigen (CEA), liver tumor burden, and chemotherapy-related characteristics including use of biologics and lines of chemotherapy (all p > 0.05). The HAI group had a better OS than the Y90 group (31.2 vs. 16.3 months; p < 0.001). A trend toward reduced cost favored the HAI group (median, $29,479 vs. $39,092; p = 0.296). The multivariate analysis showed that receipt of HAI (hazard ratio 0.465) and number of chemotherapy lines (HR 0.797) were associated with improved OS from the date of IU-CRCLM diagnosis. Conclusions: This is the first study to evaluate the comparative effectiveness of HAI versus Y90 in the era of modern chemotherapy, and the findings suggests that HAI is associated with better survival than Y90 for patients with pretreated IU-CRCLM. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

49. Fitbit step counts during inpatient recovery from cancer surgery as a predictor of readmission.

Author

Low, Carissa A, Bovbjerg, Dana H, Ahrendt, Steven, Choudry, M Haroon, Holtzman, Matthew, Jones, Heather L, Pingpank, James F, Ramalingam, Lekshmi, Zeh, Herbert J, Zureikat, Amer H, Bartlett, David L, Pingpank, James F Jr, and Zeh, Herbert J 3rd

Subjects
WEARABLE technology, CANCER patients, PERITONEAL cancer, ONCOLOGIC surgery, POSTOPERATIVE period, PATIENT readmissions
Abstract

Background: Postoperative ambulation is encouraged to promote timely recovery but is rarely monitored objectively or examined as a predictor of clinical outcomes, despite growing availability of wearable devices that allow passive quantification and remote real-time monitoring of the number of steps taken during recovery.Purpose: To determine whether the number of steps taken during inpatient recovery predicts 30- and 60-day readmission risk after metastatic cancer surgery.Methods: Patients diagnosed with metastatic peritoneal cancer and scheduled for surgical resection were enrolled in this observational cohort study at their preoperative clinic visit. Fitbits were placed on patients' wrists upon transfer from the ICU following surgery and worn for the duration of their inpatient stay. Information about hospital readmission was extracted from electronic medical records.Results: Seventy-one patients participated in the study (mean age = 57.14, range = 31-80 years; 42% female; 51% diagnosed with appendiceal cancer). Mean steps per day were calculated for each participant over the entire inpatient recovery period (mean stay = 12.12 days, 4-37 days). Readmission within 30 and 60 days was medically indicated for 34% and 39% of patients, respectively. After statistically adjusting for age, body mass index, comorbidity, and length of postoperative stay, higher mean steps per day predicted lower 30-day and 60-day readmission risk.Conclusions: Higher Fitbit step counts during inpatient recovery predicted lower risk of 30- and 60-day readmission after surgery for metastatic peritoneal cancer. Results suggest that passively monitoring perioperative ambulation may identify patients at risk for readmission and highlight opportunities for behavioral intervention. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results